



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 62169

Title: Diagnosis and treatment of pediatric anaplastic lymphoma kinase-positive large B-cell lymphoma: A case report

Reviewer's code: 00742010

Position: Peer Reviewer

Academic degree: PhD

Professional title: Associate Professor

Reviewer's Country/Territory: Singapore

Author's Country/Territory: China

Manuscript submission date: 2020-12-31

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-01-29 08:11

Reviewer performed review: 2021-02-15 08:10

Review time: 16 Days and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This is a single case report description of a pediatric case with ALK + LBCL on the diagnosis and follow-up treatment regime with a short write up of the literature. Overall the paper is well written and descriptive with pertinent clinical and test result information to the reader. As this is a rare disease, such limited cases do add to the limited literature. Importantly is the report on targeted tyrosine kinase inhibitor treatment (Alectinib) in ALK + LBCL in a child. Minor comments include: 1. Update on the WHO classification of lymphoid neoplasms is given in the later 2016 version (Swerdlow SH et al., Blood 127(20):2375-2390). Authors used the older 2008 version. 2. Page 9, please provide manufacturer of the ALK breakapart probe used in the assay. 3. Page 10, t(2;17)(p23;q23). 4. References- Use first 6 authors followed by et al. 5. Minor word spacings are needed. Many words are joined together.